Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 60.02% is in line with its 5-year average of 58.11%, near the high end of its 5-year range (-4.87%–63.19%).
0.84% above its 12-month average of 59.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 55.18%.
GROSS MARGIN
60.02%
GROSS MARGIN AVG TTM
59.52%
GROSS MARGIN AVG 3Y
59.17%
GROSS MARGIN AVG 5Y
58.11%
GROSS MARGIN AVG 10Y
55.83%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.84%
CURRENT VS 3Y AVG
+1.44%
CURRENT VS 5Y AVG
+3.29%
CURRENT VS 10Y AVG
+7.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+43.73%
vs the sector median at left
Collegium Pharmaceutical, Inc.
Market Cap
$708.19M
Gross Margin
60.02%
TTM Avg
59.52%
3Y Avg
59.17%
5Y Avg
58.11%
Market Cap
$707.95M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$704.02M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$716.10M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$718.57M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$692.29M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$726.83M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$666.95M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. (COLL) | $708.19M | 60.02% | 59.52% | 59.17% | 58.11% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $707.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $704.02M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $716.10M | 53.23% | 53.64% | 56.38% | 57.18% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $718.57M | 100.00% | 141.50% | 99.31% | 94.19% |
| Anteris Technologies Global Corp. (AVR)vs › | $692.29M | -16.57% | 15.14% | 17.91% | 27.64% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $726.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| Annexon, Inc. (ANNX)vs › | $676.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 100.27% | 50.13% | 25.07% | 10.71% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.36M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
Gross Margin
60.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 55.18% |
| 2026-03-31 | 60.59% |
| 2025-12-31 | 62.49% |
| 2025-09-30 | 61.70% |
| 2025-06-30 | 57.65% |
| 2025-03-31 | 54.75% |
| 2024-12-31 | 54.02% |
| 2024-09-30 | 60.76% |
| 2024-06-30 | 62.51% |
| 2024-03-31 | 63.11% |
| 2023-12-31 | 63.19% |
| 2023-09-30 | 58.75% |
| 2023-06-30 | 54.47% |
| 2023-03-31 | 53.47% |
| 2022-12-31 | 38.41% |
| 2022-09-30 | 46.33% |
| 2022-06-30 | 42.38% |
| 2022-03-31 | 57.90% |
| 2021-12-31 | -4.87% |
| 2021-09-30 | 58.49% |
| 2021-06-30 | 60.57% |
| 2021-03-31 | 63.38% |
| 2020-12-31 | 58.07% |
| 2020-09-30 | 60.87% |
| 2020-06-30 | 61.96% |
| 2020-03-31 | 50.96% |
| 2019-12-31 | 33.85% |
| 2019-09-30 | 35.90% |
| 2019-06-30 | 35.16% |
| 2019-03-31 | 34.02% |
| 2018-12-31 | 59.52% |
| 2018-09-30 | 34.44% |
| 2018-06-30 | 35.89% |
| 2018-03-31 | 32.38% |
| 2017-12-31 | 89.86% |
| 2017-09-30 | 95.37% |
| 2017-06-30 | 83.79% |
| 2017-03-31 | 82.92% |
| 2016-12-31 | 85.88% |
| 2016-09-30 | 92.89% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
